VivoSim Expands ADC Toxicity Testing with NAMkind Models at SOT Meeting
Event summary
- VivoSim will present new data on NAMkind™ liver and intestine models for ADC toxicity prediction at the SOT meeting in San Diego, March 22-25, 2026.
- NAMkind™ models show close correlation with clinical results for marketed ADC therapies, particularly in liver and intestinal toxicity.
- VivoSim is scaling capacity to meet global demand for its toxicology services in the US, Europe, Korea, and China.
- The FDA's April 2025 announcement to refine animal testing requirements is expected to accelerate adoption of human tissue models.
The big picture
VivoSim's presentation at the SOT meeting underscores the growing importance of human-relevant toxicology models in ADC development, a market with hundreds of candidates in the pipeline. The company's ability to correlate model results with clinical outcomes positions it as a key player in reducing drug development risks. The FDA's regulatory shift further strengthens VivoSim's strategic advantage in the preclinical safety space.
What we're watching
- Market Expansion
- The pace at which VivoSim can scale its NAMkind™ services to meet growing global demand, particularly in Asia-Pacific.
- Regulatory Tailwinds
- How the FDA's shift toward non-animal testing methods will impact the adoption of VivoSim's models.
- Competitive Positioning
- Whether VivoSim can sustain its scientific leadership in human-relevant NAM models amid increasing competition.
Related topics